TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T45299	Tissue-type plasminogen activator	D0I0RJ	Amiloride	Approved	16231	C6H8ClN7O	229.63	C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N	IC50 = 220000 nM	Non binder
T45299	Tissue-type plasminogen activator	B05XVL	6-Fluoro-2-[2-hydroxy-3-((S)-2-methyl-4,4-dimethyl-cyclopentyloxy)-phenyl]-1H-benzoimidazole-5-carboxamidine	Investigative	136092212	C22H25FN4O2	396.5	C[C@H]1CC(C[C@@H]1OC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C(=C4)C(=N)N)F)(C)C	Ki = 425000 nM	Non binder
T45299	Tissue-type plasminogen activator	B0BRT2	(2S)-N-Cyclopentyl-N-methyl-5-[4-(methylamino)phenyl]-2-(naphthalen-2-ylsulfonylamino)pent-4-ynamide	Investigative	44264598	C28H31N3O3S	489.6	CNC1=CC=C(C=C1)C#CC[C@@H](C(=O)N(C)C2CCCC2)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3	Ki > 200000 nM	Non binder
T45299	Tissue-type plasminogen activator	B0TDN5	2-[[6-Amino-5-[(Z)-N'-hydroxycarbamimidoyl]pyrazin-2-yl]amino]acetic acid	Investigative	136264091	C7H10N6O3	226.19	C1=C(N=C(C(=N1)/C(=N/O)/N)N)NCC(=O)O	IC50 > 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	B1A0QP	4-[(2R)-3-(3-Carbamimidoylphenyl)-2-(naphthalen-2-ylsulfonylamino)propanoyl]-N,N-dimethylpiperazine-1-carboxamide	Investigative	10578280	C27H32N6O4S	536.6	CN(C)C(=O)N1CCN(CC1)C(=O)[C@@H](CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	B1GUP7	Mupain-1	Investigative	101862198	C51H73N13O16S2	1188.3	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N1)N)C(=O)O)CC(=O)O)CC(C)C)CC3=CC=C(C=C3)O)CCCN=C(N)N)CO)CC4=CC=C(C=C4)O	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	B1IKE8	(2S)-N-[(4-Aminocyclohexyl)methyl]-1-[2-(benzylsulfonylamino)-3,3-diphenylpropanoyl]pyrrolidine-2-carboxamide	Investigative	44380417	C34H42N4O4S	602.8	C1C[C@H](N(C1)C(=O)C(C(C2=CC=CC=C2)C3=CC=CC=C3)NS(=O)(=O)CC4=CC=CC=C4)C(=O)NCC5CCC(CC5)N	Ki = 6700000 nM	Non binder
T45299	Tissue-type plasminogen activator	B1J8FR	3-[(R)-3-(4-Acetyl-piperazin-1-yl)-2-(naphthalene-2-sulfonylamino)-3-oxo-propyl]-benzamidine	Investigative	10696955	C26H29N5O4S	507.6	CC(=O)N1CCN(CC1)C(=O)[C@@H](CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3	Ki = 410000 nM	Non binder
T45299	Tissue-type plasminogen activator	B1X2VI	(2S)-N-Cyclopentyl-2-[(6-methoxynaphthalen-2-yl)sulfonylamino]-N-methyl-5-[4-(methylamino)phenyl]pent-4-ynamide	Investigative	44264660	C29H33N3O4S	519.7	CNC1=CC=C(C=C1)C#CC[C@@H](C(=O)N(C)C2CCCC2)NS(=O)(=O)C3=CC4=C(C=C3)C=C(C=C4)OC	Ki > 200000 nM	Non binder
T45299	Tissue-type plasminogen activator	B1Y2TO	3-[(R)-3-(4-Methanesulfonyl-piperazin-1-yl)-3-oxo-2-(2,2,5,7,8-pentamethyl-chroman-6-sulfonylamino)-propyl]-benzamidine	Investigative	44335624	C29H41N5O6S2	619.8	CC1=C(C(=C(C2=C1OC(CC2)(C)C)C)S(=O)(=O)N[C@H](CC3=CC(=CC=C3)C(=N)N)C(=O)N4CCN(CC4)S(=O)(=O)C)C	Ki = 470000 nM	Non binder
T45299	Tissue-type plasminogen activator	B21UTS	(2S)-N-[(4-Aminocyclohexyl)methyl]-1-[2-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,9,11,13-heptaenyl)acetyl]pyrrolidine-2-carboxamide;hydrochloride	Investigative	45264998	C29H36ClN3O2	494.1	C1C[C@H](N(C1)C(=O)CC2C3=CC=CC=C3C=CC4=CC=CC=C24)C(=O)NCC5CCC(CC5)N.Cl	Ki = 268000 nM	Non binder
T45299	Tissue-type plasminogen activator	B26LPQ	6-Fluoro-2-[2-hydroxy-3-(pyrrolidin-3-yloxy)-phenyl]-1H-benzoimidazole-5-carboxamidine	Investigative	136034781	C18H18FN5O2	355.4	C1CNCC1OC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C(=C4)C(=N)N)F	Ki = 225000 nM	Non binder
T45299	Tissue-type plasminogen activator	B39FGY	3-Bromo-N-(4-guanidino-phenyl)-2-hydroxy-5-methyl-benzamide	Investigative	44304139	C15H15BrN4O2	363.21	CC1=CC(=C(C(=C1)Br)O)C(=O)NC2=CC=C(C=C2)N=C(N)N	Ki = 258000 nM	Non binder
T45299	Tissue-type plasminogen activator	B3HKL2	Tert-butyloxy carbonyl-D-Phe-DL-Pro(5,5-methyl)-Arg-H	Investigative	44358868	C27H42N6O5	530.7	CC1(CCC(N1C(=O)[C@H](CC2=CC=CC=C2)NC(=O)OC(C)(C)C)C(=O)N[C@@H](CCCN=C(N)N)C=O)C	IC50 > 30000000 nM	Non binder
T45299	Tissue-type plasminogen activator	B3IC8Q	4-Bromo-3-hydroxy-anthracene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide	Investigative	44304086	C21H16BrN5O2	450.3	C1=CC=C2C=C3C(=CC2=C1)C=C(C(=C3Br)O)C(=O)NC4=CN=C(C=C4)N=C(N)N	Ki = 506000 nM	Non binder
T45299	Tissue-type plasminogen activator	B3SZ0P	3-Hydroxy-anthracene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide	Investigative	44304087	C21H17N5O2	371.4	C1=CC=C2C=C3C=C(C(=CC3=CC2=C1)C(=O)NC4=CN=C(C=C4)N=C(N)N)O	Ki = 338000 nM	Non binder
T45299	Tissue-type plasminogen activator	B4W3NK	N-[(6-Amino-2-methylpyridin-3-yl)methyl]-1-[[4-(pyrazol-1-ylmethyl)phenyl]methyl]pyrazole-4-carboxamide	Investigative	134130781	C22H23N7O	401.5	CC1=C(C=CC(=N1)N)CNC(=O)C2=CN(N=C2)CC3=CC=C(C=C3)CN4C=CC=N4	IC50 > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	B5F9LD	Benzyl 2-[(6-amino-5-carbamoyl-3-chloropyrazin-2-yl)amino]acetate	Investigative	70689516	C14H14ClN5O3	335.74	C1=CC=C(C=C1)COC(=O)CNC2=NC(=C(N=C2Cl)C(=O)N)N	IC50 > 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	B5HLU0	(2S)-1-[(2R)-2-Acetamido-2-phenylpropanoyl]-N-[(2S)-5-(diaminomethylideneamino)-1-oxopentan-2-yl]azetidine-2-carboxamide	Investigative	10598728	C21H30N6O4	430.5	CC(=O)N[C@](C)(C1=CC=CC=C1)C(=O)N2CC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O	IC50 = 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	B5O3JK	1-Phenylguanidine	Investigative	16157	C7H9N3	135.17	C1=CC=C(C=C1)N=C(N)N	Ki = 733000 nM	Non binder
T45299	Tissue-type plasminogen activator	B5S3JN	(3R,8R,11S,14S,17S,20S,23S,26S,29S,32S)-3-Amino-20-[(1-carbamimidoylpiperidin-4-yl)methyl]-11-(carboxymethyl)-23-(hydroxymethyl)-17,26-bis[(4-hydroxyphenyl)methyl]-29-methyl-14-(2-methylpropyl)-2,10,13,16,19,22,25,28,31-nonaoxo-5,6-dithia-1,9,12,15,18,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-8-carboxylic acid	Investigative	127037469	C54H77N13O16S2	1228.4	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N1)N)C(=O)O)CC(=O)O)CC(C)C)CC3=CC=C(C=C3)O)CC4CCN(CC4)C(=N)N)CO)CC5=CC=C(C=C5)O	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	B5W6NO	(2S)-N-[(4-Aminocyclohexyl)methyl]-1-(3,3-diphenylpropanoyl)pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid	Investigative	44347573	C29H36F3N3O4	547.6	C1C[C@H](N(C1)C(=O)CC(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)NCC4CCC(CC4)N.C(=O)(C(F)(F)F)O	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	B6MVO0	n-(4-Carbamimidoyl-3-choro-phenyl)-2-hydroxy-3-iodo-5-methyl-benzamide	Investigative	4300	C15H13ClIN3O2	429.64	CC1=CC(=C(C(=C1)I)O)C(=O)NC2=CC(=C(C=C2)C(=N)N)Cl	Ki = 256000 nM	Non binder
T45299	Tissue-type plasminogen activator	B6ST8W	(2S)-N-[(4-Aminocyclohexyl)methyl]-1-(3-phenyl-3-pyridin-2-ylpropanoyl)pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid	Investigative	44347533	C28H35F3N4O4	548.6	C1C[C@H](N(C1)C(=O)CC(C2=CC=CC=C2)C3=CC=CC=N3)C(=O)NCC4CCC(CC4)N.C(=O)(C(F)(F)F)O	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	B72ERJ	2-[(6-Amino-5-carbamimidoyl-3-chloropyrazin-2-yl)amino]acetic acid	Investigative	70693724	C7H9ClN6O2	244.64	C(C(=O)O)NC1=NC(=C(N=C1Cl)C(=N)N)N	IC50 > 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	B72ZMX	3-Hydroxy-4-isopropoxy-anthracene-2-carboxylic acid (4-guanidino-phenyl)-amide	Investigative	44303912	C25H24N4O3	428.5	CC(C)OC1=C(C(=CC2=CC3=CC=CC=C3C=C21)C(=O)NC4=CC=C(C=C4)N=C(N)N)O	Ki > 563000 nM	Non binder
T45299	Tissue-type plasminogen activator	B78PHM	(2S)-N-[(2S)-5-(Diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(3S)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]pyrrolidine-2-carboxamide	Investigative	44335014	C21H30N6O3	414.5	C1C[C@H](N(C1)C(=O)[C@@H]2CC3=CC=CC=C3CN2)C(=O)N[C@@H](CCCN=C(N)N)C=O	IC50 = 430000 nM	Non binder
T45299	Tissue-type plasminogen activator	B7RI4S	2-[(6-Amino-5-carbamimidoylpyrazin-2-yl)amino]acetic acid	Investigative	70683232	C7H10N6O2	210.19	C1=C(N=C(C(=N1)C(=N)N)N)NCC(=O)O	IC50 > 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	B7W8SC	2-(3-Phenoxy-5-chloro-2-pyridinyl)guanidine	Investigative	44298511	C12H11ClN4O	262.69	C1=CC=C(C=C1)OC2=C(N=CC(=C2)Cl)N=C(N)N	Ki = 342000 nM	Non binder
T45299	Tissue-type plasminogen activator	B7XE9V	2-[[6-Amino-5-(diaminomethylidenecarbamoyl)pyrazin-2-yl]amino]acetic acid	Investigative	70695842	C8H11N7O3	253.22	C1=C(N=C(C(=N1)C(=O)N=C(N)N)N)NCC(=O)O	IC50 > 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	B85DZR	(12E)-20-Amino-22-methyl-6-(pyrazol-1-ylmethyl)-9,17-dioxa-1,21,25,29-tetrazatetracyclo[25.2.1.03,8.018,23]triaconta-3(8),4,6,12,18,20,22,27(30),28-nonaen-26-one	Investigative	134131077	C29H33N7O3	527.6	CC1=C2CNC(=O)C3=CN(CC4=C(C=C(C=C4)CN5C=CC=N5)OCC/C=C/CCCOC2=CC(=N1)N)N=C3	IC50 > 200000 nM	Non binder
T45299	Tissue-type plasminogen activator	B8U7HR	20-Amino-22-methyl-6-(pyrazol-1-ylmethyl)-9,17-dioxa-1,21,25,29-tetrazatetracyclo[25.2.1.03,8.018,23]triaconta-3(8),4,6,13,18,20,22,27(30),28-nonaen-26-one	Investigative	134131303	C29H33N7O3	527.6	CC1=C2CNC(=O)C3=CN(CC4=C(C=C(C=C4)CN5C=CC=N5)OCCCC=CCCOC2=CC(=N1)N)N=C3	IC50 > 200000 nM	Non binder
T45299	Tissue-type plasminogen activator	B9HXG4	(2S)-N-[(2S)-5-(Diaminomethylideneamino)-2-methyl-1-oxopentan-2-yl]-1-[(2S)-2-(methylamino)-3-phenylpropanoyl]pyrrolidine-2-carboxamide	Investigative	44358867	C22H34N6O3	430.5	C[C@](CCCN=C(N)N)(C=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CC=CC=C2)NC	IC50 > 30000000 nM	Non binder
T45299	Tissue-type plasminogen activator	B9I3UR	(2S)-N-[(4-Aminocyclohexyl)methyl]-1-(3-phenyl-3-pyridin-4-ylpropanoyl)pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid	Investigative	44347477	C28H35F3N4O4	548.6	C1C[C@H](N(C1)C(=O)CC(C2=CC=CC=C2)C3=CC=NC=C3)C(=O)NCC4CCC(CC4)N.C(=O)(C(F)(F)F)O	Ki = 436000 nM	Non binder
T45299	Tissue-type plasminogen activator	B9OBX0	2-Phenyl-1H-benzimidazole-5-carboxamidine	Investigative	11009950	C14H12N4	236.27	C1=CC=C(C=C1)C2=NC3=C(N2)C=C(C=C3)C(=N)N	Ki = 381000 nM	Non binder
T45299	Tissue-type plasminogen activator	B9OGL5	(3R,8R,11S,14S,17S,20S,23S,26S,29S,32S)-3-Amino-23-benzyl-20-[(1-carbamimidoylpiperidin-4-yl)methyl]-26-[3-(diaminomethylideneamino)propyl]-11-(1H-indol-3-ylmethyl)-17,29-dimethyl-14-(2-methylpropyl)-2,10,13,16,19,22,25,28,31-nonaoxo-5,6-dithia-1,9,12,15,18,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-8-carboxylic acid	Investigative	127037264	C58H85N17O11S2	1260.5	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N1)N)C(=O)O)CC3=CNC4=CC=CC=C43)CC(C)C)C)CC5CCN(CC5)C(=N)N)CC6=CC=CC=C6)CCCN=C(N)N	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	BCKD46	6-Fluoro-2-[2-hydroxy-3-(piperidin-3-ylmethoxy)-phenyl]-1H-benzoimidazole-5-carboxamidine	Investigative	136092210	C20H22FN5O2	383.4	C1CC(CNC1)COC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C(=C4)C(=N)N)F	Ki = 263000 nM	Non binder
T45299	Tissue-type plasminogen activator	BF0WL6	(2S)-N-[(2S)-5-(Diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(2R)-2-phenyl-2-[(2,2,2-trifluoroacetyl)amino]propanoyl]pyrrolidine-2-carboxamide	Investigative	10505479	C22H29F3N6O4	498.5	C[C@@](C1=CC=CC=C1)(C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCN=C(N)N)C=O)NC(=O)C(F)(F)F	IC50 > 30000000 nM	Non binder
T45299	Tissue-type plasminogen activator	BF1A5S	(3R,8R,11S,14S,17S,20S,23S,26S,29S,32S)-3-Amino-11,23-dibenzyl-20-[(1-carbamimidoylpiperidin-4-yl)methyl]-26-[3-(diaminomethylideneamino)propyl]-17,29-dimethyl-14-(2-methylpropyl)-2,10,13,16,19,22,25,28,31-nonaoxo-5,6-dithia-1,9,12,15,18,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-8-carboxylic acid	Investigative	127036086	C56H84N16O11S2	1221.5	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N1)N)C(=O)O)CC3=CC=CC=C3)CC(C)C)C)CC4CCN(CC4)C(=N)N)CC5=CC=CC=C5)CCCN=C(N)N	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	BF4K6S	N-(4-Guanidino-phenyl)-2-hydroxy-3-iodo-5-methyl-benzamide	Investigative	44304100	C15H15IN4O2	410.21	CC1=CC(=C(C(=C1)I)O)C(=O)NC2=CC=C(C=C2)N=C(N)N	Ki > 563000 nM	Non binder
T45299	Tissue-type plasminogen activator	BF8ON7	(2S)-N-[(4-Aminocyclohexyl)methyl]-1-(3-phenyl-3-pyridin-3-ylpropanoyl)pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid	Investigative	44347479	C28H35F3N4O4	548.6	C1C[C@H](N(C1)C(=O)CC(C2=CC=CC=C2)C3=CN=CC=C3)C(=O)NCC4CCC(CC4)N.C(=O)(C(F)(F)F)O	Ki = 746000 nM	Non binder
T45299	Tissue-type plasminogen activator	BFM5W3	Vaborbactam	Investigative	56649692	C12H16BNO5S	297.14	B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O	IC50 > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	BG24AR	N-Quinolin-2-yl-guanidine	Investigative	21705171	C10H10N4	186.21	C1=CC=C2C(=C1)C=CC(=N2)N=C(N)N	Ki = 367000 nM	Non binder
T45299	Tissue-type plasminogen activator	BGD4Y8	2-(3-Bromo-5-chloro-2-pyridinyl)guanidine	Investigative	10131165	C6H6BrClN4	249.49	C1=C(C=NC(=C1Br)N=C(N)N)Cl	Ki = 272000 nM	Non binder
T45299	Tissue-type plasminogen activator	BGI7H5	3-Hydroxy-4-iodo-anthracene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide	Investigative	44304084	C21H16IN5O2	497.3	C1=CC=C2C=C3C(=CC2=C1)C=C(C(=C3I)O)C(=O)NC4=CN=C(C=C4)N=C(N)N	Ki = 225000 nM	Non binder
T45299	Tissue-type plasminogen activator	BGN96T	2-(4-Guanidynephenyl)-1-phenyl-ethanone	Investigative	44433791	C15H17N3O	255.31	C1=CC=C(C=C1)C(=O)CC2=CC=C(C=C2)NC(N)N	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	BIR2K1	3-[(R)-3-(4-Methyl-piperazin-1-yl)-2-(naphthalene-2-sulfonylamino)-3-oxo-propyl]-benzamidine	Investigative	10648370	C25H29N5O3S	479.6	CN1CCN(CC1)C(=O)[C@@H](CC2=CC(=CC=C2)C(=N)N)NS(=O)(=O)C3=CC4=CC=CC=C4C=C3	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	BJ7RE1	2-[[6-Amino-3-chloro-5-(diaminomethylidenecarbamoyl)pyrazin-2-yl]amino]acetic acid	Investigative	11277660	C8H10ClN7O3	287.66	C(C(=O)O)NC1=NC(=C(N=C1Cl)C(=O)N=C(N)N)N	IC50 > 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	BL3G5E	(2S)-N-[(4-Aminocyclohexyl)methyl]-1-[3-(1,3-benzodioxol-5-yl)-3-pyridin-3-ylpropanoyl]pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid	Investigative	44347623	C29H35F3N4O6	592.6	C1C[C@H](N(C1)C(=O)CC(C2=CC3=C(C=C2)OCO3)C4=CN=CC=C4)C(=O)NCC5CCC(CC5)N.C(=O)(C(F)(F)F)O	Ki > 500000 nM	Non binder
T45299	Tissue-type plasminogen activator	BL5HO1	3-Hydroxy-4-isopropoxy-anthracene-2-carboxylic acid (6-guanidino-pyridin-3-yl)-amide	Investigative	44303925	C24H23N5O3	429.5	CC(C)OC1=C(C(=CC2=CC3=CC=CC=C3C=C21)C(=O)NC4=CN=C(C=C4)N=C(N)N)O	Ki = 300000 nM	Non binder
T45299	Tissue-type plasminogen activator	BLW8V5	2-[3-[(E)-2-(2-Pyridinyl)ethenyl]-5-chloro-2-pyridinyl]guanidine	Investigative	44298510	C13H12ClN5	273.72	C1=CC=NC(=C1)/C=C/C2=C(N=CC(=C2)Cl)N=C(N)N	Ki = 258500 nM	Non binder
T45299	Tissue-type plasminogen activator	BQ57NV	(13Z)-20-Amino-22-methyl-6-(pyrazol-1-ylmethyl)-9,17-dioxa-1,21,25,29-tetrazatetracyclo[25.2.1.03,8.018,23]triaconta-3(8),4,6,13,18,20,22,27(30),28-nonaen-26-one	Investigative	134131084	C29H33N7O3	527.6	CC1=C2CNC(=O)C3=CN(CC4=C(C=C(C=C4)CN5C=CC=N5)OCCC/C=C\\CCOC2=CC(=N1)N)N=C3	IC50 > 200000 nM	Non binder
T45299	Tissue-type plasminogen activator	BQT31C	2-[[6-Amino-3-chloro-5-[(Z)-N'-hydroxycarbamimidoyl]pyrazin-2-yl]amino]acetic acid	Investigative	136268735	C7H9ClN6O3	260.64	C(C(=O)O)NC1=NC(=C(N=C1Cl)/C(=N/O)/N)N	IC50 > 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	BT40PV	(2S)-N-[(2S)-5-(Diaminomethylideneamino)-2-methyl-1-oxopentan-2-yl]-1-[(3S)-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]pyrrolidine-2-carboxamide	Investigative	44358866	C22H32N6O3	428.5	C[C@](CCCN=C(N)N)(C=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]2CC3=CC=CC=C3CN2	IC50 > 30000000 nM	Non binder
T45299	Tissue-type plasminogen activator	BTES06	6-Fluoro-2-[2-hydroxy-3-(pyrrolidin-2-ylmethoxy)-phenyl]-1H-benzoimidazole-5-carboxamidine	Investigative	136092216	C19H20FN5O2	369.4	C1C[C@@H](NC1)COC2=CC=CC(=C2O)C3=NC4=C(N3)C=C(C(=C4)C(=N)N)F	Ki = 275000 nM	Non binder
T45299	Tissue-type plasminogen activator	BV2UF1	alpha-(Benzyloxycarbonylamino)-4-guanidinobenzylphosphonic acid diphenyl ester	Investigative	11445130	C28H27N4O5P	530.5	C1=CC=C(C=C1)COC(=O)NC(C2=CC=C(C=C2)N=C(N)N)P(=O)(OC3=CC=CC=C3)OC4=CC=CC=C4	IC50 = 250000 nM	Non binder
T45299	Tissue-type plasminogen activator	BX2VY0	(3R,8R,11S,14S,17S,20S,23S,26S,29S,32S)-3-Amino-29-(4-aminobutyl)-11,23-dibenzyl-20-[(1-carbamimidoylpiperidin-4-yl)methyl]-26-[3-(diaminomethylideneamino)propyl]-17-methyl-14-(2-methylpropyl)-2,10,13,16,19,22,25,28,31-nonaoxo-5,6-dithia-1,9,12,15,18,21,24,27,30-nonazabicyclo[30.3.0]pentatriacontane-8-carboxylic acid	Investigative	127035672	C59H91N17O11S2	1278.6	C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC3CCN(CC3)C(=N)N)CC4=CC=CC=C4)CCCN=C(N)N)CCCCN)N)C(=O)O)CC5=CC=CC=C5)CC(C)C	Ki > 1000000 nM	Non binder
T45299	Tissue-type plasminogen activator	BZYL38	(8e)-3-Amino-1-Methyl-15-[(1h-Pyrazol-1-Yl)methyl]-7,10,11,12,24,25-Hexahydro-6h,18h,23h-19,22-(Metheno)pyrido[4,3-J][1,9,13,17,18]benzodioxatriazacyclohenicosin-23-One	Investigative	134131589	C29H33N7O3	527.6	CC1=C2CNC(=O)C3=CN(CC4=C(C=C(C=C4)CN5C=CC=N5)OCCC/C=C/CCOC2=CC(=N1)N)N=C3	IC50 > 200000 nM	Non binder
T45299	Tissue-type plasminogen activator	D07SFI	Benzamidine	Investigative	2332	C7H8N2	120.15	C1=CC=C(C=C1)C(=N)N	Ki = 910000 nM	Non binder
T45299	Tissue-type plasminogen activator	D0F6EZ	(4-guanidino-benzyl)-carbamic acid benzyl ester	Investigative	44436702	C16H18N4O2	298.34	C1=CC=C(C=C1)COC(=O)NCC2=CC=C(C=C2)N=C(N)N	Ki > 1000000 nM	Non binder